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ABSTRACT
Introduction: Demoralization is a relatively neglected issue in which low morale and poor cop-
ing result from a stressor such as familial cancer risk. Female BRCA1/2 mutation carriers are
highly susceptible for developing breast and ovarian cancer. The aim of this study was to evalu-
ate demoralization in oophorectomized BRCA1/2 mutation carriers and its relation to quality of
life.
Methods: This cross-sectional study examined 288 oophorectomized BRCA1/2 mutation carriers
using the following standardized self-report measures: Demoralization Scale, EORTC Quality of
Life Questionnaire-C30, State-Trait Anxiety Inventory and the Cancer Worry Scale.
Results: The mean score on the Demoralization Scale was 17.8 (SD 14.0). A clinically significant
level of demoralization, defined as a score 30, was found in 45 BRCA1/2 mutation carriers
(16%). Being highly demoralized was associated with a significantly lower quality of life, and
higher levels of physical problems, anxiety and cancer worries. No demographic or clinical fac-
tors could predict higher levels of demoralization.
Conclusions: Our findings established that a clear proportion of oophorectomized BRCA1/2
mutation carriers experience demoralization impacting on their well-being. Further research is
needed to explore the natural trajectory of demoralization and the resultant need for support in
these women.
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Introduction
Evidence grows showing that demoralization is a rele-
vant factor influencing psychological well-being in
patients with cancer and other medical diseases [1,2].
Demoralization, as described by Frank [3], is experi-
enced as a persistent inability to cope, together with
feelings of helplessness, hopelessness, meaningless-
ness, subjective incompetence and diminished self-
esteem. It is the burden of disease or suffering from a
specific condition which highly determines the need
for professional support, advocating for measures to
assess the well-being of individual patients [4].
Women with a germline mutation in one of the two
breast cancer genes (BRCA1 and BRCA2) are at high
risk for developing breast and ovarian cancer, 40–80%
and 18–60%, respectively [5–7]. To handle these high
risks, female BRCA1/2 mutation carriers have to make
decisions about risk-reducing strategies potentially
affecting both physical and psychological well-being.
Options for breast cancer risk reduction consist of
intensive surveillance or risk-reducing mastectomy
(RRM), with the latter substantially reducing the breast
cancer risk, but survival benefits are not yet confirmed
[8,9]. Because of the absence of effective screening for
ovarian cancer combined with its poor prognosis [10],
risk-reducing salpingo-oophorectomy (RRSO) is
strongly recommended to all BRCA1/2 mutation car-
riers around the age of 40 years [11]. RRSO highly
reduces the risk of ovarian cancer [12,13], although a
residual risk of peritoneal cancer (1–4%) remains
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[14,15]. Adverse effects of premature surgical meno-
pause include short-term (e.g. vasomotor symptoms,
sexual dysfunction) and possible long-term effects
(e.g. osteoporosis, cardiovascular disease), which may
not be fully alleviated by hormone replacement ther-
apy (HRT) [16–21].
Besides physical consequences, aspects of psycho-
logical distress are studied in BRCA1/2 mutation carriers.
After risk-reducing surgery, health-related quality of life
in BRCA1/2 mutation carriers is unaffected or only
briefly diminished, and general and cancer-
specific distress are decreased [22–27]. The level of
depressive symptoms and general anxiety have been
low and seem to be unaffected by RRSO [22,23,28].
In addition to physical and psychological functioning,
existential well-being is an important determinant of
quality of life [29]. Demoralization, as described by
Clarke and Kissane [30], is a clearly defined syndrome of
existential distress occurring in patients suffering from
physical and psychiatric illness, including ones that
threaten life or integrity of being. Hopelessness, the hall-
mark of demoralization, is associated with poor out-
comes in illness [30–32], and seems to be associated
with a significantly increased risk of relapse or death at
5 and 10 years after early-stage breast cancer [33,34]. In
cancer patients, demoralization is negatively associated
with quality of life, and positively related to depression,
anxiety and physical problems. Demoralization is
not associated with cancer-related factors such as
time since diagnosis, stage of disease and type of
treatment [2].
Concepts of demoralization or existential distress
have hardly had any attention in research in BRCA1/2
mutation carriers of whom a substantial part may
become breast cancer survivors at some point in their
lives. BRCA1/2 mutation carriers are generally exposed
to various overwhelming circumstances concerning
health and family matters. The majority will be able to
cope with existential challenges in the context of being
a BRCA1/2mutation carrier, and they may react with per-
sonal growth and a heightened sense of meaning and
purpose in life [35]. At the other end of the spectrum of
responses to existential challenges, helplessness, hope-
lessness, confusion, low morale and pessimism might
occur when patients feel they have failed their own or
others’ expectations for coping with these life events,
and then they may become demoralized [30].
Demoralization might be a harbinger of clinical
depression, exist co-morbidly with it or occur quite
independently of depression [2]. Depression is particu-
larly characterized by anhedonia, the diminished ability
to experience pleasure; whereas, demoralization is
marked by low morale, pessimism and helplessness,
without affecting the ability to enjoy the
present moment [30,36]. Differentiation between
demoralization and depression is of clinical importance
in guiding the choice of appropriate therapy [30,37,38].
The aim of this study was to evaluate the level of
demoralization in oophorectomized BRCA1/2 mutation
carriers and to test our hypothesis that higher levels of
demoralization would be related to lower quality of life.
Methods
Participants and procedure
We performed a cross-sectional observational study of
BRCA1/2 mutation carriers who underwent RRSO using
validated questionnaires to assess demoralization,
quality of life, general and specific anxiety. A total of
629 BRCA1/2 mutation carriers were identified at the
Department of Obstetrics and Gynaecology of
Radboud university medical center, Nijmegen, the
Netherlands. All these BRCA1/2 mutation carriers were
counseled at the Familial Cancer Clinic organizing inte-
grated care for BRCA1/2 mutation carriers within the
context of a multidisciplinary team including all profes-
sionals involved in prevention and management of
breast and ovarian cancer (clinical geneticists, gyneco-
logic oncologists, medical oncologists, (plastic) sur-
geons, pathologists, radiologists and social workers).
During counseling by the gynecologic oncologists,
BRCA1/2 mutation carriers were told about their esti-
mated lifetime risk of ovarian cancer, RRSO as only evi-
dence-based approach to reduce ovarian cancer risk,
recommended age for RRSO, the effect of RRSO on
ovarian cancer risk and menopause and possibility of
HRT use. Of all identified women, 156 were excluded
for not having an RRSO yet (n¼ 129), being deceased
(n¼ 16) or diagnosed with ovarian cancer (n¼ 11). In
total, 473 BRCA1/2 mutation carriers were eligible for
participation and underwent an RRSO between
November 1995 and May 2011 (Figure 1), and were
informed by letter about the aim and content of the
study in June 2011. When consenting to participate,
they were invited to fill in a digital questionnaire.
Participation was strictly voluntary and the survey was
confidential and anonymous. Questionnaires contained
demographic and clinical information (age, parity,
highest level of education, type of BRCA mutation,
date of BRCA mutation analysis, date of RRSO, HRT
use, hysterectomy, history of breast cancer, family his-
tory of breast and/or ovarian cancer and RRM). This
study was not subject to the Dutch “Medical Research
Involving Human Subjects Act” meaning no ethical
approval was needed from the institutional review
board of the Radboud university medical center.
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Measures
The Dutch version of the Demoralization Scale (DS) is a
24-item self-report, validated questionnaire, developed
to assess demoralization across cognitive, emotional,
motivational and social dimensions [31,39].
Respondents report the frequency of each item over
the last two weeks on a five-point Likert scale ranging
from 0 (“never”) to 4 (“all the time”). The DS has five
subscales describing loss of meaning and purpose (5
items), dysphoria (5 items), disheartenment (6 items),
helplessness (4 items) and sense of failure (4 items). In
this study, the DS had a Cronbach’s alpha of 0.95; for
the subscales it ranged between 0.78 and 0.89. A total
score may range from 0 to 96, and higher scores indi-
cate more demoralization. The cutoff scores 30 and
36 were used to indicate moderate and high demor-
alization, respectively [31,35,40]. The DS is able to dif-
ferentiate a subset of patients who are demoralized
and yet not clinically depressed [1,2].
The European Organization for Research and
Treatment of Cancer (EORTC) developed a valid and
reliable instrument measuring the quality of life of
cancer patients: the Quality of Life Questionnaire-Core
30 (EORTC QLQ-C30) (Dutch version 3) [41,42]. The
EORTC QLQ-C30 is composed of both multi-item scales
and single-item measures including five functional
scales (physical, role, emotional, cognitive, social),
three symptoms scales (fatigue, pain, nausea/vomit-
ing), a global health status scale and six single items
(dyspnoea, insomnia, appetite loss, constipation, diar-
rhea, financial difficulties), all concerning the past
week. All of the scales range in score from 0 to 100.
Higher scores in the global health status and function-
ing scales and lower scores in the symptom scale indi-
cate better quality of life.
General anxiety was assessed using the Dutch ver-
sion of the Spielberger State-Trait Anxiety Inventory
(STAI) [43,44]. It contains two separate 20-item sub-
scales that measure state anxiety (present anxiety) and
trait anxiety (anxiety in general as a personality trait).
The global score for each form is calculated as the
sum of the 20 items ranging from 20 to 80. Higher
scores indicate more severe anxiety.
To assess patients’ worries about the remaining risk
of peritoneal cancer in the previous month, the Dutch
version of the 8-item Cancer Worry Scale (CWS) was
used. The CWS was originally designed as a six-item
scale to measure worry about cancer recurrence and
the impact of worry on daily functioning [45,46].
Douma et al. [47] added two general items to address
worries about family members and future surgery
(items 7 and 8). We specifically asked for the fear of
the remaining risk of peritoneal cancer (items 1–6)
instead of cancer in general, and thereby we left the
fear of (recurrent) breast cancer out of consideration.
Scores range from 8 to 32. In breast cancer survivors,
a cutoff score of 13 (low) versus 14 (high) seemed
optimal to detect severe levels of fear [48].
Statistical analysis
We computed the sum scores of the validated ques-
tionnaires as indicated. We handled the less than 1%
missing data of the DS by imputing items from multi-
item scales: subscales were calculated if at least half of
the items from that subscale were completed. Means
and percentages were used to describe baseline char-
acteristics and all measured psychological variables.
We tested the distribution of the data for normality
using Kolmogorov–Smirnov. The DS was categorized
into three groups (low <30; moderate 30–35; high
>35) [31,35,40]. Correlations were used to test associa-
tions between the three levels of demoralization and
other psychological and physical problems. Univariate
logistic analysis was used to identify demographic and
clinical factors associated with high demoralization.
Statistical analysis was performed using SPSS software
version 20.0 (SPSS Inc., Chicago, IL). A two-sided p val-
ues <.05 was considered statistically significant.
Results
Participants
In total 473 women were invited to participate, of who
292 (62%) completed the questionnaire. Data from
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Figure 1. Flow chart of recruitment.
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four women were excluded because in three cases
more than 50% of item responses were missing, and
in one case the total DS score could not be calculated
because of missing values. The final study sample con-
sisted of 288 BRCA1/2 mutation carriers (Figure 1).
Characteristics of all participants are listed in Table 1.
Of the excluded women for not having an RRSO (yet),
120 of 129 (93%) were under or at the recommended
age of RRSO.
Demoralization and psychological factors
The results for demoralization, quality of life, anxiety
and worries about future peritoneal cancer are
reported in Table 2. A clinically relevant level of
demoralization was found in 45 BRCA1/2 mutation car-
riers (16%); 15 women were moderately demoralized
(5.2%) and 30 women were highly demoralized
(10.4%).
The mean score on global health status in oopho-
rectomized BRCA1/2 mutation carriers was 76.3 (SD
17.6). Overall, the specific quality of life measured by
the five functioning scales was high, and symptoms
were low, in particular, the global level of emotional
functioning did not suggest concern for clinical
depression.
Worries about peritoneal cancer were generally low
in BRCA1/2 mutation carriers. Especially, specific wor-
ries about residual risk of peritoneal cancer (items 1–6)
were low (6.8 (SD 1.6)); 65% of the women had no
worries about this risk at all, and only six women (2%)
reported (very) frequent worries. General worries
(items 7 and 8) about risk of cancer in their family or
potential need for (additional) surgery in the future
were reported in a substantial part of the BRCA1/2
mutation carriers, 32% and 10%, respectively. When
using the cutoff score from the literature to detect
severe levels of fear of recurrence [48], in our study
12% of the BRCA1/2 mutation carriers reported severe
levels of worries about peritoneal cancer.
Demoralization associated with psychological,
clinical and demographic factors
Oophorectomized BRCA1/2 mutation carriers who were
highly demoralized had a significantly lower global
health status (Spearman’s rho (rs)¼0.459, p< .001),
and scored worse on all functioning dimensions
(Table 3). Regarding the item about feeling depressed
within the EORTC QLQ-C30, a high correlation with
demoralization was found (rs¼0.580, p< 0.001). Both
general anxiety and cancer worry were positively
related to demoralization. Higher levels of demoraliza-
tion were also associated with more physical prob-
lems, especially fatigue and insomnia (rs¼ 0.338 and
rs¼ 0.349, both p< .001). Furthermore, a correlation
was found between financial difficulties and demoral-
ization (rs¼ 0.327, p< .001) (Table 3). No demographic
or clinical factors were associated with moderate to
high demoralization using univariate logistic analysis;
and therefore no multivariate logistic regression was
performed (Table 4).
Discussion
Overall, low levels of demoralization were found in
oophorectomized BRCA1/2 mutation carriers; although,
for a substantial minority (16%) clinically relevant lev-
els of demoralization occurred. Being demoralized
was significantly associated with lower quality of life
and higher levels of general and cancer-specific
anxiety.
Table 1. Demographic and clinical characteristics of the
respondents (n¼ 288).
Variable N (%)
Demographic characteristics
Age; mean (SD); range 51.3 (8.4); 36–76 years
Parity
0 34 (12)
1–2 163 (57)
3 91 (31)
Level of education
Primary education 10 (4)
Secondary education 191 (66)
Higher education 87 (30)
Clinical characteristics
Mutation
BRCA 1 182 (63)
BRCA 2 106 (37)
Personal history of breast cancer (missing¼ 1)
No 187 (65)
Yes 100 (35)
Risk-reducing mastectomy (missing¼ 1)
No 164 (57)
Yes 76 (27)
Contralateral mastectomy after breast cancer 47 (16)
Family cancer history (missing¼ 1)
No 5 (2)
Breast cancer 118 (41)
Ovarian cancer 19 (7)
Breast and ovarian cancer 139 (48)
Cancer, not further specified 6 (2)
Degree of family cancer history (missing¼ 3)
First degree 202 (72)
Only second degree 77 (28)
Age at RRSO; mean (SD) 45.7 (8.3)
Time since RRSO in months; median (range) 53.5 (2–235)
Hysterectomy (missing¼ 24)
No 247 (94)
Yes 17 (6)
Use of HRTa (missing¼ 2)
Never 179 (63)
0–5 years 77 (26)
>5 years 30 (11)
Values are expressed as numbers with percentage or otherwise indicated.
aCombined estrogenþ progesterone therapy (n¼ 100); estrogen-only
therapy (n¼ 3); missing (n¼ 4).
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The levels of demoralization in oophorectomized
BRCA1/2 mutation carriers were lower than found in a
systematic review of cancer patients in general [2].
Unfortunately, data on demoralization in the general
population are lacking; only one Dutch study on
demoralization in opioid-dependent patients used a
community-based sample and cancer patients as refer-
ence groups, reporting a slightly higher level of
demoralization in the community-based sample than
in our study [39].
In mainly Italian studies, demoralization has been
assessed by a categorical measurement, the Diagnostic
Criteria for Psychosomatic Research (DCPR) [49] report-
ing demoralization in 20–34% of the patients with dif-
ferent medical diseases [50–54]. Comparing this
structured interview with the DS, the DS appears to be
more clinically useful as it is likely that demoralization
exists on a continuum ranging from what would be a
normal response to one that would be characterized
as dysfunctional. In addition, the most recent edition
of the DSM, the DSM-V [55], acknowledges the limita-
tions of categorical diagnosis and has shifted the con-
ceptualization of some disorders to a dimensional
focus.
Concentrating on the clinical significance of demor-
alization, different thresholds have been utilized to
quantify meaningful presence of demoralization
[2,31,35,40]. For our study, we used the cutoff scores
for moderate demoralization (30–35) and high demor-
alization (36), derived from studies by Kissane et al.
[31] and Vehling et al. [35,40]. Moderate and high lev-
els of demoralization in cancer patients were observed
in 8–11% and 9–17%, respectively [35,40,56] which is
higher than our results.
Overall, we found normal to high levels of general
and specific quality of life, and low levels of anxiety.
Our results are in accordance with studies on theTable 2. Demoralization, quality of life and anxiety.
Variable Mean (SD)
Normal ranges of
measures
Demoralization
Total demoralization score 17.8 (14.0) 0–96
Loss of meaning and purpose 1.9 (3.2) 0–20
Dysphoria 4.8 (3.4) 0–24
Disheartenment 4.6 (4.2) 0–20
Helplessness 2.7 (3.2) 0–16
Sense of failure 3.9 (2.3) 0–16
Health-related quality of life
Global health status/Quality of life 76.6 (17.1) 0–100
Physical functioning 93.5 (12.2) 0–100
Role functioning 91.8 (16.9) 0–100
Emotional functioning 84.2 (19.7) 0–100
Cognitive functioning 84.8 (20.7) 0–100
Social functioning 90.4 (18.0) 0–100
Anxiety
State anxiety 34.6 (11.4) 20–80
Trait anxiety 34.6 (11.0) 20–80
Cancer worries 10.7 (2.3) 8–32
Table 3. Correlations between demoralization and psychological and physical variables.
Low demoralization Moderate demoralization High demoralization
N¼ 243 N¼ 15 N¼ 30 Spearman’s rho
Global health status 80.3 (14.3) 60.7 (13.5) 55.2 (19.7) 0.459
Physical functioning 95.5 (9.4) 80.4 (17.9) 84.0 (18.8) 0.319
Role functioning 94.5 (12.4) 78.9 (29.1) 76.7 (26.8) 0.314
Emotional functioning 89.0 (14.7) 67.8 (14.7) 52.9 (24.9) 0.506
Cognitive functioning 88.1 (17.9) 71.4 (24.8) 63.8 (25.6) 0.366
Social functioning 93.9 (13.2) 70.8 (25.7) 70.6 (27.9) 0.418
State anxiety 31.5 (8.3) 43.7 (8.0) 54.9 (11.1) 0.537
Trait anxiety 31.4 (7.6) 46.5 (5.5) 55.0 (10.7) 0.577
Cancer worries 10.4 (1.9) 11.7 (2.1) 12.6 (3.2) 0.271
Fatigue 13.2 (16.3) 28.1 (18.2) 37.8 (26.7) 0.338
Nausea and vomiting 1.4 (6.7) 3.3 (6.9) 5.6 (10.1) 0.219
Pain 8.3 (16.4) 24.4 (28.8) 26.7 (28.6) 0.269
Dyspnoea 3.7 (11.3) 8.9 (19.8) 12.2 (18.5) 0.207
Insomnia 19.9 (25.6) 42.2 (23.5) 46.7 (25.7) 0.349
Appetite loss 1.9 (8.4) 0 16.7 (22.7) 0.298
Constipation 6.5 (15.5) 24.4 (29.5) 12.2 (23.9) 0.168
Diarrhea 2.6 (10.8) 0 6.7 (20.3) 0.042
Financial difficulties 2.1 (9.3) 11.9 (31.0) 21.8 (32.5) 0.327
Values are expressed as mean (SD).p values <.01.
Table 4. Univariate logistic analysis for moderate to high
demoralization (DS 30) by demographic and clinical factors.
Exp(B) 95% CI p value
Demographic factors
Age 1.004 0.97–1.04 .82
Having children 1.81 0.76–4.29 .18
Higher education 1.41 0.68–2.93 .36
Clinical factors
BRCA2 mutation 1.07 0.55–2.07 .85
History of breast cancer 0.69 0.36–1.32 .26
Risk-reducing mastectomy 1.53 0.70–3.35 .29
Family member with ovarian cancer 1.09 0.57–2.06 .80
Mother with breast or ovarian cancer 0.81 0.42–1.57 .53
Age at RRSO 0.996 0.96–1.04 .84
Time since RRSO 1.003 0.996–1.01 .39
RRSO >1 year ago 0.74 0.27–2.01 .56
HRT after RRSO 1.39 0.70–2.75 .34
RRSO: risk-reducing salpingo-oophorectomy; HRT: hormone replacement
therapy.
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impact of RRSO on quality of life and anxiety, report-
ing normal levels and no changes after RRSO, although
further comparisons seems difficult due to small sam-
ples and different study populations, designs and
questionnaires [22,23,57,58,59,60].
To our knowledge, worries about residual risk of
peritoneal cancer after RRSO have not been studied
previously; we found low levels of fear of residual
risk of peritoneal cancer. Twelve percent of all
BRCA1/2 mutation carriers had a severe level of wor-
ries, which is lower compared to earlier studies
showing that about 20% of the women still had sig-
nificant ovarian cancer-specific worries after RRSO
[22,58,59]. Most of the reported worries in our study
were about risk of cancer in family members and
future surgery. Possible explanations for low worries
about peritoneal cancer could be that women were
not (well) informed about the residual risk, could
not remember the given information, or concluded
that the residual risk of 1–4% is small, and not
worth worrying about.
We found a strong negative association between
demoralization and health-related quality of life.
Anxiety, depression and cancer worries were highly
related to demoralization. The relationships between
quality of life, depression and anxiety to demoraliza-
tion were consistently confirmed in the literature on
cancer patients, and mixed results were reported for
age, education and cancer site [2]. Uniformly, no asso-
ciation was found between demoralization and time
since diagnosis, stage of disease and type of treatment
[2]. In our sample, no association was found for age,
parity, education level, history of breast cancer, HRT
use after RRSO, family history and RRM.
Presumably, many physicians will meet demoral-
ized patients, and the confusion with depressed
patients is easily made when not being familiar with
the concept of demoralization. When a threat occurs
that we need to cope with, we normally sustain our
morale. If disappointment or a mild or fleeting level
of demoralization occurs, we help with encourage-
ment and support. But once moderate or severe
demoralization occurs, clinicians can do a lot to help
assuage this distress and impairment. In addition,
Clarke and Kissane [30] stated that helping a demo-
ralized person is the role of every health professional
and is achieved most importantly through a relation-
ship characterized by empathic resonance, combined
with good physical care and symptomatic relief. It
may be helpful for physicians to familiarize them-
selves with the concept of demoralization to better
inform and support BRCA1/2 mutation carriers who
exhibit symptoms of demoralization.
Highly demoralized persons could benefit from spe-
cialist support. Different styles of psychotherapy may
usefully address specific problems in a demoralized
patient, including brief bed-side therapy and meaning-
centered psychotherapy [37,38,61]. Strong support is
provided for the efficacy of meaning-centered psycho-
therapy for hopelessness, as a hallmark of demoraliza-
tion, in advanced cancer patients [61–63]. We are
waiting for results of a randomized controlled trial
started on this concept in cancer survivors [64].
Furthermore, differentiation between depression and
demoralization is relevant in the treatment setting
[65–67]: antidepressant medication helps patients who
have depression/melancholia but by itself does little to
relieve demoralization, while psychotherapy is helpful
in demoralized patients, but has limited effects for
patients who have entrenched anhedonia [38].
Qualitative research could be useful to explore in-
depth the experiences of BRCA1/2 mutation carriers
with demoralization. Further longitudinal research
could provide insight in the natural trajectory of
demoralization in BRCA1/2 mutation carriers and its
relation to the specific events allied to being a BRCA1/
2 mutation carrier.
To our knowledge, we are the first to describe the
concept of demoralization in oophorectomized BRCA1/
2 mutation carriers. The large sample size is a strength
of our study. Important limitations of our study are
the cross-sectional design, and the lack of controls.
The presence of demoralization will change over time;
however, our study gives no insight into this.
Unfortunately, we did not measure depression with a
validated depression scale to explore its comorbidity
with or differentiation from demoralization, which
should be assessed in further research.
In conclusion, demoralization is low in oophorec-
tomized BRCA1/2 mutation carriers; although a sub-
stantial minority has clinically relevant levels of
demoralization. Demoralization is highly associated
with lower quality of life, and higher anxiety.
Detecting demoralization in BRCA1/2 mutation carriers
could be useful because these women face different
stressful circumstances related to being a BRCA1/2
mutation carrier, potentially arousing existential dis-
tress. Identifying highly demoralized BRCA1/2 mutation
carriers gives the opportunity to offer appropriate
treatment to contribute to a better quality of life.
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 Current knowledge on the subject
 Hopelessness is the hallmark of demoralization.
 Demoralization influences well-being in cancer patients.
 Being a female BRCA1/2 mutation carrier has physical and psychological impact.
What this study adds
 Demoralization is generally low in oophorectomized BRCA1/2 mutation carriers.
 One out of six BRCA1/2 mutation carriers are moderately to highly demoralized.
 Being demoralized has a negative impact on well-being in BRCA1/2 mutation carriers.
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